A placebo-controlled trial with citalopram for the treatment of typical reflux symptoms in patients with reflux hypersensitivity or functional heartburn with incomplete proton pump inhibitor response.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517019-57-00

Enrollment

100

Registered

2024-10-23

Start date

2018-04-10

Completion date

Unknown

Last updated

2024-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastro-esophageal reflux disease

Brief summary

Change in number of reflux episodes

Detailed description

Change in volume exposure of reflux, Change in number of reflux episodes with a high proximal extent, Change in esophageal sensitivity, Change in symptom severity, Predictive value of reflux assessment, assessment of esophageal sensitivity and reflux questionnaire

Interventions

DRUGPlacebo tablet manufactured by Laboratoria Wolfs

DRUGZwijndrecht. Ingredients (1 tablet

DRUG488mg): Lactose monohydrate 320mg Carmellose sodium 10mg Corn starch 70mg Cellulose microcrystalline 55mg Silicium dioxide anhydrous 20mg Magnesium stearate 13mg

DRUGCitalopram Viatris 20 mg filmomhulde tabletten

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change in number of reflux episodes	—

Secondary

Measure	Time frame
Change in volume exposure of reflux, Change in number of reflux episodes with a high proximal extent, Change in esophageal sensitivity, Change in symptom severity, Predictive value of reflux assessment, assessment of esophageal sensitivity and reflux questionnaire	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026